Annual Reports AI — AI-powered financial intelligence platformAnnual Reports AI
HEALTHCARE · NSE/BSE: CAPLIPOINT

Caplin Point Laboratories Limited Earnings Summary — Q4 FY2026

Sentiment: Positive
AI-generated summary
Generated 2026-06-23

Caplin Point Reports Strong Q4 FY26 Performance with 32% Sales Growth and Robust Margins

Net Profit
₹173 Cr
YoY 19.31%
QoQ 4.22%
Prior: ₹166 Cr
Revenue
₹600 Cr
YoY 19.52%
QoQ 10.50%
Prior: ₹543 Cr
Operating Margin
34%
YoY +100 bps
QoQ -100 bps
Prior: 35%
Dividend Yield
—
Payout ratio for FY26 is 5%
Net Debt / Equity
0.001
YoY -97.72%
Prior: 0.08

Key Takeaways

  • Revenue reached an all-time quarterly high of INR 600 Cr in Q4 FY26.
  • Operating Profit Margin remains industry-leading at 34%, despite ongoing investments in US compliance.
  • The company has effectively achieved a zero-debt status with borrowings falling to just INR 5 Cr.
  • Net Profit continues its upward trajectory, growing nearly 20% compared to the same quarter last year.
  • The company maintains a strong cash position and high capital efficiency with ROCE exceeding 25%.
  • Successfully transitioning toward a vertically integrated model while managing a massive portfolio of 4,000+ licenses.

Management Guidance

Management remains focused on expanding the 'Caplin Steriles' footprint in the US market through internal accruals and leveraging its dominant position in Latin America and Africa.

Sentiment Shift

Stable

Consistent performance across all financial metrics with a notable deleveraging of the balance sheet confirms a high-quality growth trajectory.

Growth-Oriented
Efficient
Debt-Free
Niche-Focused

Outlook

The outlook remains strong as the company pivots toward regulated markets like the US while maintaining high-margin dominance in frontier markets. Expansion is funded entirely via internal cash flows.

From the Annual Report (Key Quotes)

“Caplin Point is a rare niche-focused pharmaceutical player that has successfully transitioned from a trading-led model to a vertically integrated manufacturer.”

“The founder’s vision of focusing on 'bottom of the pyramid' markets has built a wide moat that larger pharmaceutical companies struggle to penetrate.”

“The company remains almost debt-free with a surplus cash position.”

Earnings Call Transcript — Q4 FY2026

Open original
## “Caplin Point Laboratories Q4 FY26 Earnings Conference Call”

# May 14, 2026

### MANAGEMENT: MR. C.C. PAARTHIPAN – CHAIRMAN MR. VIVEK PARTHEEBAN – VICE-CHAIRMAN

### MR. ASHOK PARTHEEBAN – VICE-CHAIRMAN DR. SRIDHAR GANESAN – MANAGING DIRECTOR

### MR. D. MURALIDHARAN – CHIEF FINANCIAL OFFICER MR. M. SATHYA NARAYANAN – DEPUTY CHIEF

### FINANCIAL OFFICER

### MODERATOR: MS. JULIE MEHTA – 360 ONE CAPITAL MARKET PRIVATE LIMITED

#### Page 1 of 18

* * *

Moderator:

Moderator: Ladies and gentlemen, good day and welcome to Caplin Point Laboratories Q4 FY26 Earnings
Conference Call hosted by 360 ONE Capital Market Private Limited.

|  | As a reminder, all participant lines will be in listen-only mode. There will be an opportunity for you to ask questions after the presentation concludes. Should you need any assistance during this conference, please signal for an operator by pressing star and then zero on your touchone telephone. Please note that this conference call is being recorded. |
| --- | --- |
|  | I now hand the conference over to Ms. Julie Mehta from 360 ONE Capital Market Private Limited. Thank you and over to you ma'am. |
| Julie Mehta: | Thank you Farah, and good afternoon, everyone. On behalf of 360 ONE Capital, we would like to welcome you all to the Q4 FY26 Conference Call of Caplin Point Laboratories Limited. |
|  | Today, we have with us Senior Management of the company represented by Mr. C.C. Paarthipan- Chairman;Mr. Vivek Partheeban-Vice-Chairman;Mr. Ashok Partheeban-Vice-Chairman;Dr. Sridhar Ganesan-Managing Director,Mr.D.Muralidharan-CFO and Mr.M Sathya Narayanan-Deputy Chief Financial Officer. |
|  | I would now like to hand the conference over to Caplin Point Management for the Opening Remarks. Over to you,sir. |
| Vivek Partheeban: | Thank you,Julie. Thank you,everyone,for joining and welcome to ourQ4&FY26Results&EarningsCall. |
|  | Please note that a copy of all our disclosures are available on the investor section of our website as well as on the stock exchanges,and also do note that anything said on this call which reflects our outlook for the future or which could be construed as a forward-looking statement must be reviewed in conjunction with the risks that the company faces. |
|  | The conference call is being recorded and the transcript along with the audio will be made available on the company's website as well as the exchanges. |
|  | Please do note that audio conference call is copyright material of Caplin Point and cannot be copied, rebroadcasted or attributed in press or media without specific written consent of the company. |
|  | I would like to now hand over the floor to Chairman for his Opening Remarks. |
| C.C. Paarthipan: | Thank you.Good evening and Welcome to our Investors Call. |

As a reminder, all participant lines will be in listen-only mode. There will be an opportunity for you
to ask questions after the presentation concludes. Should you need any assistance during this
conference, please signal for an operator by pressing star and then zero on your touchtone telephone.
Please note that this conference call is being recorded.

I now hand the conference over to Ms. Julie Mehta from 360 ONE Capital Market Private Limited.
Thank you and over to you ma'am.

Julie Mehta: Thank you Farah, and good afternoon, everyone. On behalf of 360 ONE Capital, we would like to
welcome you all to the Q4 FY26 Conference Call of Caplin Point Laboratories Limited.

Today, we have with us Senior Management of the company represented by Mr. C.C. Paarthipan –
Chairman; Mr. Vivek Partheeban –Vice-Chairman; Mr. Ashok Partheeban – Vice-Chairman; Dr.
Sridhar Ganesan – Managing Director, Mr. D. Muralidharan – CFO and Mr. M Sathya Narayanan –
Deputy Chief Financial Officer.

I would now like to hand the conference over to Caplin Point Management for the Opening Remarks.
Over to you, sir.

Vivek Partheeban:

Please note that a copy of all our disclosures are available on the investor section of our website as
w

…

Source: NSE — Latest Concall Transcript

Ask AI about this earnings call

Sign in to ask AI questions grounded on the full earnings call transcript.

This summary is AI-generated from Caplin Point Laboratories Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.

← Back to Caplin Point Laboratories Limited AI analysis